First Week of January 2026 Options Trading For Masimo (MASI)

The piece outlines two option strategies on Masimo Corp. (MASI, current price $149.01): selling a $140 put with a $4.10 bid (net cost basis if assigned $135.90) which Stock Options Channel estimates has a 69% chance of expiring worthless and would produce a 2.93% return (20.17% annualized) if so; and selling a $150 covered call (bid $8.50) after buying at $149.01 that would yield 6.37% total if called at the January 2026 expiration and has a 47% chance of expiring worthless, representing a 5.70% (39.28% annualized) YieldBoost. Implied volatilities are ~45% (put) and 44% (call) versus a 12‑month realized volatility of 41%; commissions and dividends are excluded.

Analysis

Market structure: option buyers demand for this mid‑cap med‑tech raises implied vol above recent realized levels, benefiting volatility sellers and liquidity providers while pressuring levered long holders who pay for hedges. This dynamic can compress effective financing costs for opportunistic acquirers and make buy‑write yield harvesting attractive for income desks over the next 6–12 months. Cross‑asset: a meaningful move in the name would have small direct FX/commodity impact but could increase correlation with rates‑sensitive healthcare names and lift med‑tech IVs, propagating gamma hedging flows into equities and single‑stock CDS.

Risk assessment: tail risks include a surprise FDA action, reimbursement shock or a material revenue miss — each could halve market cap in a stress episode; clinical or safety headlines would spike IV 20–40 vol points within days. Immediate risk is theta/IV roll in options trades; medium term (3–9 months) hinges on earnings and regulatory catalysts; long term depends on adoption/reimbursement trends and margin profile versus competitors. Hidden dependencies: hospital capex cycles and OEM supply chains can create delayed demand shocks; vendor concentration or single‑product revenue exposure amplifies downside.

Trade implications: for stock exposure prefer option‑wrapped entry to collect premia and set explicit buy zones (e.g., size initial exposure at 1–3% of portfolio, increase on pullbacks >15%). Use cash‑secured puts ~8–12% below spot or buy‑write with calls ~3–6% OTM and 9–18 month tenor to target asymmetric carry while capping upside; layer protective puts (15% OTM) if net long. Consider a relative trade: long MASI vs short IHI (or a large diversified med‑tech like MDT) to isolate stock‑specific upside; scale out on a 20% outperformance gap.

Contrarian angles: consensus underprices event risk despite elevated IV — implieds can collapse if no negative catalyst, creating fast premium erosion and convex losses for short volatility. The yield on covered strategies may be compensating for liquidity and idiosyncratic risks; if fundamentals reaccelerate, option sellers will underperform as IV compresses. Historical parallels show beaten med‑techs can gap higher post regulatory clarity, so keep optionality (long calls or call spreads) sized to capture asymmetric upside while preserving income.

Key Decisions for Investors

• Initiate a 1–3% portfolio long in MASI via cash‑secured puts placed ~8–12% below current spot with target net premium income ~2–4% (annualized carry >15%); allocate capital to be assigned shares and scale up if assigned and price drops another 10%.
• Establish a buy‑write: purchase MASI for up to 2% portfolio weight and sell 9–18 month calls ~3–6% OTM to lock in 4–7% income to call; roll calls if underlying rallies >20% or if IV collapses >10 vol points.
• If already long MASI, purchase a 12‑month put ~15% OTM when drawdown >8% or if protective cost ≤3% of position value to limit tail loss to ~15% while keeping upside optionality.
• Put on a relative‑value pair: go long MASI and short IHI (notional matched) for 6–12 months to exploit stock‑specific recovery; trim if MASI outperforms by 20% or if IHI outperforms by 10%.
• Cut position by 50% within 48 hours if any of these occur: FDA denial or clinical safety alert, revenue guidance miss >10%, or IV gap up >30 vol points — redeploy proceeds into long calls if IV remains elevated and fundamentals intact.